Condition: Testicular Cancer, Seminoma, Quality of Life, De-escalation, RPLND

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT07498959

Sponsor: Sahlgrenska University Hospital

Eligibility:

• Age: minimum 18 Years maximum N/A
• Gender: Male

Inclusion Criteria:

• Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A/B (maximum 2 nodes, <30 mm in any dimension)
• Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, <30 mm in any dimension)
• Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)

Exclusion Criteria:

• Previous chemotherapy (including adjuvant chemotherapy at diagnosis)
• Previous RPLND
• Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires

View trial on ClinicalTrials.gov